↓ Skip to main content

Pharmacogenomics in Drug Discovery and Development

Overview of attention for book
Cover of 'Pharmacogenomics in Drug Discovery and Development'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 From Pharmacogenomics and Systems Biology to Personalized Care: A Framework of Systems and Dynamical Medicine
  3. Altmetric Badge
    Chapter 2 Translational Bioinformatics Approaches for Systems and Dynamical Medicine
  4. Altmetric Badge
    Chapter 3 Whole Blood Transcriptomic Analysis to Identify Clinical Biomarkers of Drug Response
  5. Altmetric Badge
    Chapter 4 Diagnostic Procedures for Paraffin-Embedded Tissues Analysis in Pharmacogenomic Studies
  6. Altmetric Badge
    Chapter 5 Approach to Clinical and Genetic Characterization of Statin-Induced Myopathy
  7. Altmetric Badge
    Chapter 6 Pharmacogenetics of membrane transporters: a review of current approaches.
  8. Altmetric Badge
    Chapter 7 G protein-coupled receptor accessory proteins and signaling: pharmacogenomic insights.
  9. Altmetric Badge
    Chapter 8 G protein-coupled receptor mutations and human genetic disease.
  10. Altmetric Badge
    Chapter 9 Pharmacogenetics of the g protein-coupled receptors.
  11. Altmetric Badge
    Chapter 10 Pharmacogenomics of Heart Failure
  12. Altmetric Badge
    Chapter 11 Pharmacogenomics in the Development and Characterization of Atheroprotective Drugs
  13. Altmetric Badge
    Chapter 12 Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neuropathy
  14. Altmetric Badge
    Chapter 13 Pharmacogenomics of Alzheimer's disease: novel therapeutic strategies for drug development.
  15. Altmetric Badge
    Chapter 14 Pharmacogenetics of antipsychotic treatment in schizophrenia.
  16. Altmetric Badge
    Chapter 15 Pharmacogenetics of addiction therapy.
  17. Altmetric Badge
    Chapter 16 Pharmacogenetics in Rheumatoid Arthritis
  18. Altmetric Badge
    Chapter 17 Pharmacogenomics of Osteoporotic Fractures
  19. Altmetric Badge
    Chapter 18 Pharmacogenomics and Pharmacoepigenomics in Pediatric Medicine
  20. Altmetric Badge
    Chapter 19 Pharmacogenomics in Children
Attention for Chapter 14: Pharmacogenetics of antipsychotic treatment in schizophrenia.
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
4 X users

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
48 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Pharmacogenetics of antipsychotic treatment in schizophrenia.
Chapter number 14
Book title
Pharmacogenomics in Drug Discovery and Development
Published in
Methods in molecular biology, January 2014
DOI 10.1007/978-1-4939-0956-8_14
Pubmed ID
Book ISBNs
978-1-4939-0955-1, 978-1-4939-0956-8
Authors

Jennie G Pouget, Daniel J Müller, Jennie G. Pouget, Daniel J. Müller, Pouget, Jennie G., Müller, Daniel J.

Abstract

Antipsychotics are the mainstay treatment for schizophrenia. There is large variability between individuals in their response to antipsychotics, both in efficacy and adverse effects of treatment. While the source of interindividual variability in antipsychotic response is not completely understood, genetics is a major contributing factor. The identification of pharmacogenetic markers that predict antipsychotic efficacy and adverse reactions is a growing area of research, and holds the potential to replace the current trial-and-error approach to treatment selection in schizophrenia with a personalized medicine approach.In this chapter, we provide an overview of the current state of pharmacogenetics in schizophrenia treatment. The most promising pharmacogenetic findings are presented for both antipsychotic response and commonly studied adverse reactions. The application of pharmacogenetics to schizophrenia treatment is discussed, with an emphasis on the clinical utility of pharmacogenetic testing and directions for future research.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 48 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 17%
Other 5 10%
Student > Master 5 10%
Researcher 5 10%
Student > Bachelor 4 8%
Other 9 19%
Unknown 12 25%
Readers by discipline Count As %
Medicine and Dentistry 11 23%
Biochemistry, Genetics and Molecular Biology 6 13%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Agricultural and Biological Sciences 3 6%
Computer Science 2 4%
Other 9 19%
Unknown 14 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 May 2015.
All research outputs
#13,337,173
of 22,761,738 outputs
Outputs from Methods in molecular biology
#3,560
of 13,088 outputs
Outputs of similar age
#162,423
of 305,296 outputs
Outputs of similar age from Methods in molecular biology
#148
of 596 outputs
Altmetric has tracked 22,761,738 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 13,088 research outputs from this source. They receive a mean Attention Score of 3.3. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 305,296 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 596 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.